Pirche

PUBLISHED BY

Aylin Akifova, Klemens Budde, Kerstin Amann, Maike Buettner-Herold, Mira Choi, Michael Oellerich, Julia Beck, Kirsten Bornemann-Kolatzki, Ekkehard Schütz, Friederike Bachmann, Fabian Halleck, Ellen von Hoerschelmann, Nadine Koch, Eva Schrezenmeier, Evelyn Seelow, Johannes Waiser, Bianca Zukunft, Kai-Uwe Eckardt, Jan Halbritter, Ralph Kettritz, Covadonga López Del Moral, Nils Lachmann, Diana Stauch, Matthias Niemann, Danilo Schmidt, Philip F Halloran, Bilgin Osmanodja

PUBLISHED IN

Nephrology Dialysis Transplantation

PATIENTS

ABSTRACT

HIGHLIGHTS

Donor-derived cell-free DNA (dd-cfDNA) shows promise in diagnosing antibody-mediated rejection (AMR) in kidney transplant recipients (KTR), with potential clinical benefits for early detection and treatment.

A single-center, randomized clinical trial compared dd-cfDNA-guided biopsy to clinician-guided biopsy in 40 KTR with donor-specific anti-HLA antibodies (dnDSA) over 12 months.

dd-cfDNA monitoring significantly reduced time to AMR diagnosis (median 2.8 vs. 14.5 months, p = 0.003), with positive and negative predictive values of 77% and 85%, respectively.

The study concludes that dd-cfDNA-guided biopsy expedites AMR diagnosis and treatment initiation in KTR with dnDSA.

‍

back to key milestones

2024

Solid Organ Transplant

Donor-derived cell-free DNA monitoring for early diagnosis of antibody-mediated rejection after kidney transplantation: a randomized trial

PUBLISHED BY

PUBLISHED IN

PATIENTS

ABSTRACT

HIGHLIGHTS

Contact us